Insulin secretion triggered by glucose is potentiated by the activation of receptors coupled to G proteins (Galphas) (RCPGs), such as the GLP-1 (RGLP-1) or GPR-119 receptors. The agonists of these receptors have been widely studied for treating type 2 diabetes. In order to better characterize and compare the insulinosecretor and/or antiapoptotic abilities of these receptor agonists, we have developed a new multi-parametric approach based on HTRF technology and which enables key parameters to be followed simultaneously: insulin secretion, the production of second messengers (cAMP), and the activation of survival transcription factors, such as CREB (cAMP-responsive element binding protein), by phosphorylation.
We are committed to your privacy. Revvity needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our Privacy Policy.
©2023 Revvity - All rights reserved